Invitation to BioInvent Capital Markets Day on November 8, 2011

LUND, Sweden--(BUSINESS WIRE)-- We have the pleasure to invite participants of the capital market and media to BioInvent’s first Capital Markets Day. The event will take place on November 8 in Wallenbergsalen, Kungl. Ingenjörsvetenskapsakademin (IVA), Grev Turegatan 16, Stockholm.

Presentations will start at 8:00 and end at around 14.00. Breakfast and lunch will be served during the course of the meeting.

The meeting will focus on BioInvent’s clinical portfolio with presentations of both external and internal speakers. The final agenda will be released later at the BioInvent home page.

A webcast will be available for those unable to attend in person. Please register for the meeting by mailing no later than October 27 to [email protected].

Looking forward to see you on November 8!

Svein Mathisen, CEO
and
Sten Westerberg, VP Investor Relations

-- END –

Notes to Editors:

About BioInvent

BioInvent International AB, listed on the NASDAQ OMX Stockholm (BINV), is a research-based

pharmaceutical company that focuses on developing antibody drugs. The Company currently has four clinical development projects within the areas of thrombosis, cancer and atherosclerosis. The Company has signed various strategic alliances to strengthen the product pipeline and increase the likelihood of success. These partners include Genentech, Human Genome Sciences, Roche and ThromboGenics.

The company’s competitive position is underpinned by an in substance patented antibody development platform. The scope and strength of this platform is also utilised by partners, such as Bayer HealthCare, Daiichi Sankyo, Mitsubishi Tanabe, UCB and XOMA. More information is available at www.bioinvent.com.

Information disclosed in this press release is provided herein pursuant to the Swedish Securities Markets Act and/or the Swedish Financial Instruments Trading Act. The information was submitted for publication at 8.30 a.m. CET, on 12 September, 2011.



CONTACT:

BioInvent International AB
Svein Mathisen
President & CEO
Tel: +46 (0)46-286 85 67
Mobile: +46 (0)708-97 82 13
E-mail: [email protected]
or
Sten Westerberg
Vice President, Investor Relations
Tel: +46 (0)46-286 85 52
Mobile: +46 (0)768-68 50 09
E-mail: [email protected]
or
College Hill (media enquiries)
Melanie Toyne Sewell, Anastasios Koutsos
Tel: +44 (0)20 7866 7856
Rebecca Skye Dietrich
Tel: -1 (857) 241-0795
E-mail: [email protected]
or
BioInvent International AB (publ)
Co. reg. No. 556537-7263,
Tel: +46 (0)46 286 85 50
[email protected]
www.bioinvent.com

KEYWORDS:   Europe  Sweden

INDUSTRY KEYWORDS:   Health  Biotechnology  Clinical Trials  Pharmaceutical

MEDIA:

Logo
 Logo

Suggested Articles

Combining inhibitors of KRAS-G12C, mTOR and IGF1R can significantly shrink lung tumors in mice and human cancer cells, a study found.

X4 Pharmaceuticals has a new R&D chief: Renato Skerlj, who founded the company alongside CEO Paula Ragan and biotech luminary Henri Termeer.

Henlius Biotech missed the $477 million goal it set for its IPO, but still made the top five biopharma IPOs this year with its $410 million listing.